Investment Management Corp of Ontario Has $1.43 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Investment Management Corp of Ontario raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 28.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,463 shares of the company's stock after buying an additional 773 shares during the period. Investment Management Corp of Ontario's holdings in IDEXX Laboratories were worth $1,432,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in IDEXX Laboratories by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after acquiring an additional 37,734 shares in the last quarter. Bamco Inc. NY boosted its holdings in shares of IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after buying an additional 82,264 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after buying an additional 74,324 shares during the last quarter. Norges Bank bought a new stake in IDEXX Laboratories during the fourth quarter worth $412,258,000. Finally, Northern Trust Corp raised its position in IDEXX Laboratories by 18.6% during the fourth quarter. Northern Trust Corp now owns 912,874 shares of the company's stock worth $377,419,000 after acquiring an additional 143,369 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded up $2.57 during trading on Thursday, reaching $511.99. The company's stock had a trading volume of 469,341 shares, compared to its average volume of 649,616. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business's 50-day moving average price is $427.95 and its 200-day moving average price is $430.50. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88. The firm has a market cap of $41.18 billion, a PE ratio of 47.98, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business's revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.71 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on IDXX shares. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Bank of America upped their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Finally, StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $524.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.